This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAmyris (AMRS *) 주식 개요Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. 자세히 보기AMRS * 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장2/6과거 실적0/6재무 건전성2/6배당0/6강점수익은 연간 27.43% 증가할 것으로 예상됩니다.위험 분석의미 있는 시가총액이 없습니다(MX$37K)마이너스 주주 지분주식은 유동성이 매우 낮습니다지난 1년 동안 주주가 희석되었습니다.+ 위험 1건 추가모든 위험 점검 보기AMRS * Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueMex$Current PriceMex$1.0095.6% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-620m901m2016201920222025202620282031Revenue US$901.3mEarnings US$85.7mAdvancedSet Fair ValueView all narrativesFeatured narrative•Materials opportunityUpside Gold2 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 저평가 내재 할인율An Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative14.8kusers have viewed this narrative42users have liked this narrative1users have commented on this narrative285users have followed this narrativeRead narrativeAmyris, Inc. 경쟁사Plasma SystemSymbol: WSE:PSMMarket cap: zł878.7kCuraScientificSymbol: OTCPK:CSTFMarket cap: US$5.5kRecyctec HoldingSymbol: NGM:RECY BMarket cap: SEK 9.0mP.V. Nano CellSymbol: OTCPK:PVNN.FMarket cap: US$25.2k가격 이력 및 성과Amyris 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$1.0052주 최고가US$41.0052주 최저가US$1.00베타1.281개월 변동0%3개월 변동0%1년 변동-97.07%3년 변동n/a5년 변동n/aIPO 이후 변동-99.66%최근 뉴스 및 업데이트공지 • May 08+ 3 more updatesKathy L. Fortmann to Join Amyris, Inc. as Member of the Board of DirectorsAmyris, Inc. announced that Ms. Kathy L. Fortmann, along with Scott White, will join John Doerr and Ryan Panchadsaram as members of the Board of Directors of Amyris. Ms. Fortmann brings almost 35 years of global business experience across a range of industries including specialty chemicals and ingredients. She most recently served as Chief Executive Officer of ACOMO N.V. from 2021 to 2023. Prior to that, Ms. Fortmann held various roles at International Flavors & Fragrances Inc. ("IFF") from 2020 until 2021, including Division President of Nourish, Division Chief Executive Officer, Taste, and Head, Taste Strategy and Cross Fertilization. Prior to IFF, she was a senior executive at FrieslandCampina from 2017 to 2019, serving as Business Group President, Ingredients and a member of the Executive Committee. From 2005 until 2017, Ms. Fortmann held various leadership positions at Cargill, Incorporated. Prior to Cargill, she held positions of increasing responsibility at E.I. DuPont de Nemours, Inc. from 1989 until 2005. Ms. Fortmann currently serves as a director on the boards of FMC Corporation and PPG.공지 • Apr 03Amyris, Inc. announced delayed annual 10-K filingOn 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Jan 24Third Amended Joint Reorganization Plan Filed by Amyris, Inc.Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding.공지 • Jan 06Foris Ventures Provides Information to the ShareholdersOn January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets.공지 • Dec 28Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities.공지 • Nov 14Amyris, Inc. announced delayed 10-Q filingOn 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.더 많은 업데이트 보기Recent updates공지 • May 08+ 3 more updatesKathy L. Fortmann to Join Amyris, Inc. as Member of the Board of DirectorsAmyris, Inc. announced that Ms. Kathy L. Fortmann, along with Scott White, will join John Doerr and Ryan Panchadsaram as members of the Board of Directors of Amyris. Ms. Fortmann brings almost 35 years of global business experience across a range of industries including specialty chemicals and ingredients. She most recently served as Chief Executive Officer of ACOMO N.V. from 2021 to 2023. Prior to that, Ms. Fortmann held various roles at International Flavors & Fragrances Inc. ("IFF") from 2020 until 2021, including Division President of Nourish, Division Chief Executive Officer, Taste, and Head, Taste Strategy and Cross Fertilization. Prior to IFF, she was a senior executive at FrieslandCampina from 2017 to 2019, serving as Business Group President, Ingredients and a member of the Executive Committee. From 2005 until 2017, Ms. Fortmann held various leadership positions at Cargill, Incorporated. Prior to Cargill, she held positions of increasing responsibility at E.I. DuPont de Nemours, Inc. from 1989 until 2005. Ms. Fortmann currently serves as a director on the boards of FMC Corporation and PPG.공지 • Apr 03Amyris, Inc. announced delayed annual 10-K filingOn 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Jan 24Third Amended Joint Reorganization Plan Filed by Amyris, Inc.Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding.공지 • Jan 06Foris Ventures Provides Information to the ShareholdersOn January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets.공지 • Dec 28Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities.공지 • Nov 14Amyris, Inc. announced delayed 10-Q filingOn 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Sep 08Nasdaq to Delist the Common Stock of AmyrisOn September 7, 2023, The Nasdaq Stock Market announced that it will delist the common stock of Amyris, Inc. Amyris, Inc.’s securities were suspended on August 21, 2023, and have not traded on Nasdaq since that time.공지 • Sep 02Amyris, Inc. Appoints Scott White as A Class II DirectorOn August 29, 2023, Amyris Inc. appointed Scott White as a Class II director, effective immediately, and with a term expiring at the company’s 2024 annual meeting of stockholders. The board determined that Mr. White qualifies as an independent director pursuant to the listing standards of the Nasdaq Stock Market. Mr. White will serve as a member of the Restructuring Committee of the Board. Mr. White is currently President and Chief Executive Officer of Edsal Manufacturing, where he has served since 2019. Mr. White has over 30 years of experience in global finance, marketing and general management roles. Prior to joining Edsal, from 2016 to 2019, Mr. White served as CEO of New Avon, a leading provider of cosmetics and beauty products. Prior to that, from 2005 to 2016, he held multiple senior management roles over 10 years at Abbott Laboratories, including President of Abbott Nutrition International. Mr. White began his career at Procter & Gamble where he served for 15 years. Mr. White currently serves as a member of the board of directors of Edsal, a privately held company. Mr. White holds an M.B.A. from Northwestern University Kellogg School of Management and a B.S. in Finance from Miami University.공지 • Aug 23+ 1 more updateMotion for Joint Administration Filed by Amyris, Inc.Amyris, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on August 21, 2023. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Clean Beauty Collaborative Inc., Clean Beauty 4U Holdings, LLC and Clean Beauty 4U LLC, with its own case for administrative and procedural purposes. Amyris, Inc. has been proposed as the lead debtor.공지 • Aug 12Amyris' Common Stock To Be Delisted from NasdaqAs previously disclosed, on August 10, 2023, Amyris, Inc. (the “Company”) and certain of its direct and indirect subsidiaries filed a voluntary petition for relief (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. On August 10, 2023, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filings and associated public concerns raised by them, concerns regarding the residual equity interest of the existing listed securities holders and concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on August 21, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq.공지 • Aug 11+ 4 more updatesAmyris, Inc. announced delayed 10-Q filingOn 08/10/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Jun 27+ 1 more updateAmyris, Inc. Announces Executive ChangesAmyris, Inc. announced that John Melo has resigned from his role as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer.공지 • May 29Amyris Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price RequirementOn May 26, 2023, Amyris, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the ‘Minimum Bid Price Requirement’). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock which will continue to trade on The Nasdaq Global Select Market under the symbol ‘AMRS’. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 22, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before November 22, 2023, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by November 22, 2023, the Company’s common stock will become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel. The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by November 22, 2023, including such options as effecting a reverse stock split.Breakeven Date Change • Apr 17No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.Breakeven Date Change • Apr 01No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.Breakeven Date Change • Mar 25No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.Breakeven Date Change • Mar 18No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$43.8m in 2025.Breakeven Date Change • Mar 03Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.Breakeven Date Change • Feb 17Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.공지 • Jan 31Amyris Launches 4U by Tia™ Haircare Line Exclusively At WalmartAmyris, Inc. announced the launch of 4U by TiaTM, a new haircare line available exclusively at Walmart. Founded by actress and entrepreneur Tia Mowry, 4U by Tia will be sold in over 2,800 Walmart retail stores in the U.S, on Walmart.com, and on the direct-to-consumer website 4UbyTia.com. Amyris will be operating the brand as part of its clean beauty portfolio of brands. The brand is launching with a full line of eight products formulated for 2A to 4C (curly) hair, all of which contain Amyris' patented Hemi15TM, a breakthrough ingredient that nourishes and protects textured hair. The line is 100% vegan, silicone-free, sulfate-free and paraben-free. Hemi15 is created using Amyris' proprietary Lab-to-Market platform, which leverages precision fermentation to create molecules that are bioidentical to those found in nature and traditionally derived from finite sources (including animals, plants, or petrochemicals) to create sustainable ingredients and provide better, healthier options for the products people use every day.Breakeven Date Change • Jan 24Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 75% is required to achieve expected profit on schedule.Breakeven Date Change • Dec 19No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024.Breakeven Date Change • Nov 28No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024.Breakeven Date Change • Oct 20Forecast to breakeven in 2024The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.Recent Insider Transactions • Sep 08Chief Legal Officer & Secretary recently sold Mex$287k worth of stockOn the 2nd of September, Nicole Kelsey sold around 5k shares on-market at roughly Mex$57.25 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger sale from another insider worth Mex$2.4m. Insiders have been net sellers, collectively disposing of Mex$1.5m more than they bought in the last 12 months.Recent Insider Transactions • Aug 18President recently bought Mex$1.4m worth of stockOn the 15th of August, John Melo bought around 17k shares on-market at roughly Mex$80.06 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by Mex$1.1m.Breakeven Date Change • Aug 11Forecast to breakeven in 2024The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.Reported Earnings • Aug 10Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.048 profit in 2Q 2021)Second quarter 2022 results: US$0.34 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$65.2m (up 25% from 2Q 2021). Net loss: US$110.0m (down US$125.4m from profit in 2Q 2021). Over the next year, revenue is forecast to grow 91% compared to a 2.5% decline forecast for the industry in Mexico.Recent Insider Transactions • Jul 09President recently sold Mex$2.4m worth of stockOn the 6th of July, John Melo sold around 56k shares on-market at roughly Mex$44.05 per share. This was the largest sale by an insider in the last 3 months. This was John's only on-market trade for the last 12 months.Recent Insider Transactions • Jun 06CFO & Chief Administration Officer recently sold Mex$1.6m worth of stockOn the 2nd of June, Hermanus Kieftenbeld sold around 35k shares on-market at roughly Mex$45.73 per share. This was the largest sale by an insider in the last 3 months. Hermanus has been a seller over the last 12 months, reducing personal holdings by Mex$8.8m.Board Change • Feb 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Ana Dutra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 03High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Ana Dutra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Jan 08Forecast to breakeven in 2024The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$78.6m in 2024. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$78.6m in 2024. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Recent Insider Transactions • Dec 12Independent Director recently bought Mex$2.1m worth of stockOn the 6th of December, James McCann bought around 17k shares on-market at roughly Mex$121 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold Mex$41m more in shares than they bought in the last 12 months.Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.37 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$47.9m (up 40% from 3Q 2020). Net loss: US$32.9m (loss narrowed 61% from 3Q 2020).Recent Insider Transactions • Sep 05CFO & Chief Administration Officer recently sold Mex$7.2m worth of stockOn the 2nd of September, Hermanus Kieftenbeld sold around 24k shares on-market at roughly Mex$297 per share. In the last 3 months, there was an even bigger sale from another insider worth Mex$30m. This was Hermanus' only on-market trade for the last 12 months.주주 수익률AMRS *MX ChemicalsMX 시장7D0%0.1%2.2%1Y-97.1%44.2%19.4%전체 주주 수익률 보기수익률 대 산업: AMRS *은 지난 1년 동안 44.2%의 수익을 기록한 MX Chemicals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: AMRS *은 지난 1년 동안 19.4%를 기록한 MX 시장보다 저조한 성과를 냈습니다.주가 변동성Is AMRS *'s price volatile compared to industry and market?AMRS * volatilityAMRS * Average Weekly Movementn/aChemicals Industry Average Movement5.0%Market Average Movement4.2%10% most volatile stocks in MX Market6.0%10% least volatile stocks in MX Market2.8%안정적인 주가: AMRS *의 주가는 지난 3개월 동안 MX 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine AMRS *의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트20031,598Han Kieftenbeldamyris.com더 보기Amyris, Inc. 기초 지표 요약Amyris의 순이익과 매출은 시가총액과 어떻게 비교됩니까?AMRS * 기초 통계시가총액Mex$645.56k순이익 (TTM)-Mex$10.66b매출 (TTM)Mex$4.65b0.0x주가매출비율(P/S)0.0x주가수익비율(P/E)AMRS *는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표AMRS * 손익계산서 (TTM)매출US$268.22m매출원가US$369.78m총이익-US$101.55m기타 비용US$512.99m순이익-US$614.55m최근 보고된 실적Mar 31, 2023다음 실적 발표일해당 없음주당순이익(EPS)-1.65총이익률-37.86%순이익률-229.12%부채/자본 비율-145.2%AMRS *의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/11/15 16:21종가2023/08/18 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Amyris, Inc.는 15명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관J. HorwitzBairdCarter DriscollB. Riley Securities, Inc.Susan AndersonCanaccord Genuity12명의 분석가 더 보기
Featured narrative•Materials opportunityUpside Gold2 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 저평가 내재 할인율An Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative14.8kusers have viewed this narrative42users have liked this narrative1users have commented on this narrative285users have followed this narrativeRead narrative
공지 • May 08+ 3 more updatesKathy L. Fortmann to Join Amyris, Inc. as Member of the Board of DirectorsAmyris, Inc. announced that Ms. Kathy L. Fortmann, along with Scott White, will join John Doerr and Ryan Panchadsaram as members of the Board of Directors of Amyris. Ms. Fortmann brings almost 35 years of global business experience across a range of industries including specialty chemicals and ingredients. She most recently served as Chief Executive Officer of ACOMO N.V. from 2021 to 2023. Prior to that, Ms. Fortmann held various roles at International Flavors & Fragrances Inc. ("IFF") from 2020 until 2021, including Division President of Nourish, Division Chief Executive Officer, Taste, and Head, Taste Strategy and Cross Fertilization. Prior to IFF, she was a senior executive at FrieslandCampina from 2017 to 2019, serving as Business Group President, Ingredients and a member of the Executive Committee. From 2005 until 2017, Ms. Fortmann held various leadership positions at Cargill, Incorporated. Prior to Cargill, she held positions of increasing responsibility at E.I. DuPont de Nemours, Inc. from 1989 until 2005. Ms. Fortmann currently serves as a director on the boards of FMC Corporation and PPG.
공지 • Apr 03Amyris, Inc. announced delayed annual 10-K filingOn 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Jan 24Third Amended Joint Reorganization Plan Filed by Amyris, Inc.Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding.
공지 • Jan 06Foris Ventures Provides Information to the ShareholdersOn January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets.
공지 • Dec 28Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities.
공지 • Nov 14Amyris, Inc. announced delayed 10-Q filingOn 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • May 08+ 3 more updatesKathy L. Fortmann to Join Amyris, Inc. as Member of the Board of DirectorsAmyris, Inc. announced that Ms. Kathy L. Fortmann, along with Scott White, will join John Doerr and Ryan Panchadsaram as members of the Board of Directors of Amyris. Ms. Fortmann brings almost 35 years of global business experience across a range of industries including specialty chemicals and ingredients. She most recently served as Chief Executive Officer of ACOMO N.V. from 2021 to 2023. Prior to that, Ms. Fortmann held various roles at International Flavors & Fragrances Inc. ("IFF") from 2020 until 2021, including Division President of Nourish, Division Chief Executive Officer, Taste, and Head, Taste Strategy and Cross Fertilization. Prior to IFF, she was a senior executive at FrieslandCampina from 2017 to 2019, serving as Business Group President, Ingredients and a member of the Executive Committee. From 2005 until 2017, Ms. Fortmann held various leadership positions at Cargill, Incorporated. Prior to Cargill, she held positions of increasing responsibility at E.I. DuPont de Nemours, Inc. from 1989 until 2005. Ms. Fortmann currently serves as a director on the boards of FMC Corporation and PPG.
공지 • Apr 03Amyris, Inc. announced delayed annual 10-K filingOn 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Jan 24Third Amended Joint Reorganization Plan Filed by Amyris, Inc.Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding.
공지 • Jan 06Foris Ventures Provides Information to the ShareholdersOn January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets.
공지 • Dec 28Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities.
공지 • Nov 14Amyris, Inc. announced delayed 10-Q filingOn 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Sep 08Nasdaq to Delist the Common Stock of AmyrisOn September 7, 2023, The Nasdaq Stock Market announced that it will delist the common stock of Amyris, Inc. Amyris, Inc.’s securities were suspended on August 21, 2023, and have not traded on Nasdaq since that time.
공지 • Sep 02Amyris, Inc. Appoints Scott White as A Class II DirectorOn August 29, 2023, Amyris Inc. appointed Scott White as a Class II director, effective immediately, and with a term expiring at the company’s 2024 annual meeting of stockholders. The board determined that Mr. White qualifies as an independent director pursuant to the listing standards of the Nasdaq Stock Market. Mr. White will serve as a member of the Restructuring Committee of the Board. Mr. White is currently President and Chief Executive Officer of Edsal Manufacturing, where he has served since 2019. Mr. White has over 30 years of experience in global finance, marketing and general management roles. Prior to joining Edsal, from 2016 to 2019, Mr. White served as CEO of New Avon, a leading provider of cosmetics and beauty products. Prior to that, from 2005 to 2016, he held multiple senior management roles over 10 years at Abbott Laboratories, including President of Abbott Nutrition International. Mr. White began his career at Procter & Gamble where he served for 15 years. Mr. White currently serves as a member of the board of directors of Edsal, a privately held company. Mr. White holds an M.B.A. from Northwestern University Kellogg School of Management and a B.S. in Finance from Miami University.
공지 • Aug 23+ 1 more updateMotion for Joint Administration Filed by Amyris, Inc.Amyris, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on August 21, 2023. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Clean Beauty Collaborative Inc., Clean Beauty 4U Holdings, LLC and Clean Beauty 4U LLC, with its own case for administrative and procedural purposes. Amyris, Inc. has been proposed as the lead debtor.
공지 • Aug 12Amyris' Common Stock To Be Delisted from NasdaqAs previously disclosed, on August 10, 2023, Amyris, Inc. (the “Company”) and certain of its direct and indirect subsidiaries filed a voluntary petition for relief (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. On August 10, 2023, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filings and associated public concerns raised by them, concerns regarding the residual equity interest of the existing listed securities holders and concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on August 21, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq.
공지 • Aug 11+ 4 more updatesAmyris, Inc. announced delayed 10-Q filingOn 08/10/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Jun 27+ 1 more updateAmyris, Inc. Announces Executive ChangesAmyris, Inc. announced that John Melo has resigned from his role as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer.
공지 • May 29Amyris Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price RequirementOn May 26, 2023, Amyris, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the ‘Minimum Bid Price Requirement’). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock which will continue to trade on The Nasdaq Global Select Market under the symbol ‘AMRS’. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 22, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before November 22, 2023, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by November 22, 2023, the Company’s common stock will become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel. The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by November 22, 2023, including such options as effecting a reverse stock split.
Breakeven Date Change • Apr 17No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.
Breakeven Date Change • Apr 01No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.
Breakeven Date Change • Mar 25No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.
Breakeven Date Change • Mar 18No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$43.8m in 2025.
Breakeven Date Change • Mar 03Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
Breakeven Date Change • Feb 17Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
공지 • Jan 31Amyris Launches 4U by Tia™ Haircare Line Exclusively At WalmartAmyris, Inc. announced the launch of 4U by TiaTM, a new haircare line available exclusively at Walmart. Founded by actress and entrepreneur Tia Mowry, 4U by Tia will be sold in over 2,800 Walmart retail stores in the U.S, on Walmart.com, and on the direct-to-consumer website 4UbyTia.com. Amyris will be operating the brand as part of its clean beauty portfolio of brands. The brand is launching with a full line of eight products formulated for 2A to 4C (curly) hair, all of which contain Amyris' patented Hemi15TM, a breakthrough ingredient that nourishes and protects textured hair. The line is 100% vegan, silicone-free, sulfate-free and paraben-free. Hemi15 is created using Amyris' proprietary Lab-to-Market platform, which leverages precision fermentation to create molecules that are bioidentical to those found in nature and traditionally derived from finite sources (including animals, plants, or petrochemicals) to create sustainable ingredients and provide better, healthier options for the products people use every day.
Breakeven Date Change • Jan 24Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 75% is required to achieve expected profit on schedule.
Breakeven Date Change • Dec 19No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024.
Breakeven Date Change • Nov 28No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024.
Breakeven Date Change • Oct 20Forecast to breakeven in 2024The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
Recent Insider Transactions • Sep 08Chief Legal Officer & Secretary recently sold Mex$287k worth of stockOn the 2nd of September, Nicole Kelsey sold around 5k shares on-market at roughly Mex$57.25 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger sale from another insider worth Mex$2.4m. Insiders have been net sellers, collectively disposing of Mex$1.5m more than they bought in the last 12 months.
Recent Insider Transactions • Aug 18President recently bought Mex$1.4m worth of stockOn the 15th of August, John Melo bought around 17k shares on-market at roughly Mex$80.06 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by Mex$1.1m.
Breakeven Date Change • Aug 11Forecast to breakeven in 2024The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
Reported Earnings • Aug 10Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.048 profit in 2Q 2021)Second quarter 2022 results: US$0.34 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$65.2m (up 25% from 2Q 2021). Net loss: US$110.0m (down US$125.4m from profit in 2Q 2021). Over the next year, revenue is forecast to grow 91% compared to a 2.5% decline forecast for the industry in Mexico.
Recent Insider Transactions • Jul 09President recently sold Mex$2.4m worth of stockOn the 6th of July, John Melo sold around 56k shares on-market at roughly Mex$44.05 per share. This was the largest sale by an insider in the last 3 months. This was John's only on-market trade for the last 12 months.
Recent Insider Transactions • Jun 06CFO & Chief Administration Officer recently sold Mex$1.6m worth of stockOn the 2nd of June, Hermanus Kieftenbeld sold around 35k shares on-market at roughly Mex$45.73 per share. This was the largest sale by an insider in the last 3 months. Hermanus has been a seller over the last 12 months, reducing personal holdings by Mex$8.8m.
Board Change • Feb 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Ana Dutra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 03High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Ana Dutra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Jan 08Forecast to breakeven in 2024The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$78.6m in 2024. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$78.6m in 2024. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Recent Insider Transactions • Dec 12Independent Director recently bought Mex$2.1m worth of stockOn the 6th of December, James McCann bought around 17k shares on-market at roughly Mex$121 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold Mex$41m more in shares than they bought in the last 12 months.
Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.37 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$47.9m (up 40% from 3Q 2020). Net loss: US$32.9m (loss narrowed 61% from 3Q 2020).
Recent Insider Transactions • Sep 05CFO & Chief Administration Officer recently sold Mex$7.2m worth of stockOn the 2nd of September, Hermanus Kieftenbeld sold around 24k shares on-market at roughly Mex$297 per share. In the last 3 months, there was an even bigger sale from another insider worth Mex$30m. This was Hermanus' only on-market trade for the last 12 months.
